Key takeaways
Saxagliptin (Onglyza) and alogliptin (Nesina) are both medications used to treat Type 2 diabetes and belong to the same drug class, dipeptidyl peptidase-4 (DPP-4) inhibitors. Saxagliptin is taken once daily and is available in a generic form, while alogliptin is also taken once daily and has a lower-cost generic option. Saxagliptin has been associated with a higher risk of heart failure in certain individuals, whereas alogliptin may also raise the risk of heart failure, especially in those with recent acute coronary syndrome. Both medications can cause side effects like headaches and upper respiratory tract infections, but saxagliptin is more likely to cause urinary tract infections, while alogliptin can cause symptoms of the common cold. Both medications are not first-choice treatments for Type 2 diabetes, are not approved for Type 1 diabetes, and need dose adjustment for kidney problems.
